Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multi-modal learning for inpatient length of stay prediction.
Chen J, Wen Y, Pokojovy M, Tseng TB, McCaffrey P, Vo A, Walser E, Moen S. Chen J, et al. Among authors: moen s. Comput Biol Med. 2024 Mar;171:108121. doi: 10.1016/j.compbiomed.2024.108121. Epub 2024 Feb 9. Comput Biol Med. 2024. PMID: 38382388
Metachronous colorectal cancer risk according to Lynch syndrome pathogenic variant after extensive versus partial colectomy in the Netherlands: a retrospective cohort study.
Eikenboom EL, Moen S, van Leerdam ME, Papageorgiou G, Doukas M, Tanis PJ, Dekker E, Wagner A, Spaander MCW; collaborative investigators from the Dutch Foundation for Detection of Hereditary Tumors. Eikenboom EL, et al. Among authors: moen s. Lancet Gastroenterol Hepatol. 2023 Dec;8(12):1106-1117. doi: 10.1016/S2468-1253(23)00228-5. Epub 2023 Oct 18. Lancet Gastroenterol Hepatol. 2023. PMID: 37865103
[Transparency is needed regarding serious incidents].
Moen SM, Iden P. Moen SM, et al. Tidsskr Nor Laegeforen. 2023 Feb 20;143(3). doi: 10.4045/tidsskr.22.0780. Print 2023 Feb 21. Tidsskr Nor Laegeforen. 2023. PMID: 36811426 Free article. Norwegian. No abstract available.
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial.
Trøseid M, Arribas JR, Assoumou L, Holten AR, Poissy J, Terzić V, Mazzaferri F, Baño JR, Eustace J, Hites M, Joannidis M, Paiva JA, Reuter J, Püntmann I, Patrick-Brown TDJH, Westerheim E, Nezvalova-Henriksen K, Beniguel L, Dahl TB, Bouscambert M, Halanova M, Péterfi Z, Tsiodras S, Rezek M, Briel M, Ünal S, Schlegel M, Ader F, Lacombe K, Amdal CD, Rodrigues S, Tonby K, Gaudet A, Heggelund L, Mootien J, Johannessen A, Møller JH, Pollan BD, Tveita AA, Kildal AB, Richard JC, Dalgard O, Simensen VC, Baldé A, de Gastines L, Del Álamo M, Aydin B, Lund-Johansen F, Trabaud MA, Diallo A, Halvorsen B, Røttingen JA, Tacconelli E, Yazdanpanah Y, Olsen IC, Costagliola D; EU SolidAct study group. Trøseid M, et al. Crit Care. 2023 Jan 10;27(1):9. doi: 10.1186/s13054-022-04205-8. Crit Care. 2023. PMID: 36627655 Free PMC article. Clinical Trial.
Unexplained mismatch repair deficiency: Case closed.
Eikenboom EL, Moen S, van Leeuwen L, Geurts-Giele WRR, Tops CMJ, van Ham TJ, Dinjens WNM, Dubbink HJ, Spaander MCW, Wagner A. Eikenboom EL, et al. Among authors: moen s. HGG Adv. 2022 Dec 14;4(1):100167. doi: 10.1016/j.xhgg.2022.100167. eCollection 2023 Jan 12. HGG Adv. 2022. PMID: 36624813 Free PMC article.
132 results